Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Observation Letter
ARTICLE IN PRESS
doi:
10.25259/IJDVL_576_2022

Oral ulcers and cutaneous rash as manifestations of differentiation syndrome in acute promyelocytic leukaemia

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Corresponding author: Dr. Keshavamurthy Vinay, Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. vinay.keshavmurthy@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Singh S, Mustari AP, Lad D, Parkhi M, Vinay K. Oral ulcers and cutaneous rash as manifestations of differentiation syndrome in acute promyelocytic leukaemia. Indian J Dermatol Venereol Leprol doi: 10.25259/IJDVL_576_2022

Sir,

Differentiation syndrome is a well-known complication of all-trans retinoic acid (ATRA), seen in up to 27% of acute promyelocytic leukaemia (APL) patients treated with the molecule.1 It is also reported to occur with arsenic trioxide (ATO), which is co-prescribed with all-trans retinoic acid in acute promyelocytic leukaemia patients.2 It usually manifests after 5–20 days of starting treatment and the presence of three of the following criteria should rise the suspicion of differentiation syndrome; unexplained fever, weight gain (more than 5 kgs), pleuro–pericardial effusion, pulmonary infiltrates, hypotension, respiratory distress and renal failure.1 Diagnosis is primarily based on clinical presentation, after ruling out infections. Dermatological manifestations of differentiation syndrome are less known and rarely described in the literature. Herein, we report cutaneous manifestations in a case of differentiation syndrome and review the existing literature on all-trans retinoic acid-induced mucocutaneous lesions.

A 73-year-old male patient presented with progressive breathlessness, recurrent fever and ecchymoses over bilateral upper and lower limbs of 14 days’ duration. Investigation revealed pancytopenia (haemoglobin; 7.3 g/dL; total leucocyte count; 3900/mm3 and platelet count 13000/mm3). Serum lactate dehydrogenase was 3045 IU/L, prothrombin time (PT) was 17 seconds (normal 12–15), and activated partial thromboplastin time (APTT) was 32 seconds (normal 36–35). Serum electrolytes and chest radiograph were within normal limits. Bone marrow examination showed >95% promyelocytes and fluorescence in situ hybridization for t (15:17) and polymerase chain reaction (PCR) for promyelocytic leukaemia gene–retinoic acid receptor-α (PML-RARA) was positive. Diagnosis of intermediate risk acute promyelocytic leukaemia was made3 and the patient was treated with oral all-trans retinoic acid (40 mg twice daily) and intravenous arsenic trioxide (10 mg once a day) with improvement in breathlessness, fever and ecchymoses. After three weeks, patient presented with recurrence of fever and breathlessness, painful oral ulcers and swelling and redness of both upper and lower limbs. Examination revealed multiple round to oval coalescing polycyclic superficial ulcers of size 3–4 mm with yellowish base and surrounding erythematous halo over the hard palate [Figure 1]. Patient also had bilateral pitting pedal oedema extending to lower one-third of the legs with overlying diffuse erythema and scaling including soles [Figure 2]. Patient was admitted for evaluation and all-trans retinoic acid and arsenic trioxide were withheld. At admission, blood pressure was 150/88 mm Hg, pulse rate was 90 beats per minute, respiratory rate was 21 breaths per minute, temperature was 104°F and oxygen saturation was 92–97%. On auscultation, bilateral basal crepitation was present. Investigations showed anaemia (haemoglobin; 7.9 g/dL), leucocytosis (total leucocyte count; 19,900/mm3), neutrophilia (12,500/mm3), eosinophilia (1900/mm), elevated C-reactive protein (60 mg/l), D-dimer (1728 ng/mL) and creatinine (1.4 mg/dL). Arterial blood gas analysis, liver function tests, serum procalcitonin, serum galactomannan, serum fibrinogen, coagulation profile (except D-dimer) and serum electrolytes were within normal limits. Chest radiograph showed bilateral diffuse infiltrates with right pleural effusion. Computed tomography (CT) of the chest showed bilateral ground-glass opacity and mild pleural effusion. Bronchoalveolar lavage examination (gram stain, acid-fast bacteria, periodic acid–Schiff were negative) did not show evidence of an infective aetiology. The patient was started on intravenous cefoperazone-sulbactam empirically. Three blood cultures sent 24 hours apart were sterile. Tzanck smear from the oral ulcers was negative for multinucleate giant cells. Cytomegalovirus, Epstein-Barr virus, herpes simplex virus and COVID-19 PCR were negative. Skin biopsy from the leg showed hyperkeratosis and mild superficial perivascular infiltrate of lymphocytes and occasional eosinophils [Figure 3]. The patient continued to have spikes of fever; breathlessness, oral ulcers and rash persisted despite changing the antibiotics to vancomycin and colistin. all-trans retinoic acid and/or arsenic trioxide-induced differentiation syndrome was suspected based on clinical features, lack of response to antibiotics, and history of recent intake of all-trans retinoic acid and arsenic trioxide. The patient was treated with prednisolone 40 mg per day with remarkable improvement in skin and mucosal lesions. The respiratory complaints also improved and there was a significant improvement in the chest radiograph. Prednisolone tapering was started after 10 days and stopped over one month. The patient was restarted on all-trans retinoic acid and arsenic trioxide after one month without any recurrence. Naranjo adverse drug reaction probability scale score was 3 for both all-trans retinoic acid and arsenic trioxide and 6 for a combination of all-trans retinoic acid and arsenic trioxide.

Figure 1:: Multiple oral ulcers with yellowish base and surrounding erythematous halo over the hard palate
Figure 2:: Bilateral pedal oedema with overlying diffuse erythema and scaling
Figure 3:: The skin biopsy shows hyperkeratosis and superficial dermal mild perivascular infiltrate of lymphocytes and occasional eosinophils (Haematoxylin and eosin, ×;400)

Acute promyelocytic leukaemia is a type of acute myeloid leukaemia that affects both children and adults. The first line of therapy for acute promyelocytic leukaemia is a combination of all-trans retinoic acid and arsenic trioxide. all-trans retinoic acid is a vitamin A derivative used in the treatment of acute promyelocytic leukaemia which acts via a retinoic acid receptor (RAR α, β and γ) that helps in the differentiation and apoptosis of malignant cells.4 Arsenic trioxide also helps in the differentiation of malignant cells by degrading promyelocytic leukemia gene–retinoic acid receptor-α (PML-RARA).

Differentiation syndrome is a serious, life-threatening, unpredictable clinical syndrome due to the differentiation of blast cells in acute promyelocytic leukaemia patients after induction therapy with all-trans retinoic acid and/or arsenic trioxide. It has also been reported in patients of pustular psoriasis and psoriasis vulgaris treated with acitretin.5 The precise mechanism of differentiation syndrome is unknown, but the differentiating acute promyelocytic leukaemia cells are primary mediators of inflammation. These cells have an increase in adhesive property and interleukin production that helps in transmigration through vessels, infiltration into various organs and subsequent immune-mediated organ damage. This leads to capillary leak, oedema, haemorrhage, leucocyte infiltration and release of inflammatory mediators and subsequent organ failure, commonly respiratory failure.6

The risk factors for differentiation syndrome include baseline high total leucocyte count (TLC), rapidly improving TLC and CD13 expression of leukaemic cells.7 The occurrence of differentiation syndrome is associated with an increased risk of extramedullary relapse.8 Differentiation syndrome has a spectrum of cutaneous manifestations including labial and lingual ulcers, scrotal ulcers and Sweet’s syndrome. Other all-trans retinoic acid-induced cutaneous manifestations reported are exfoliative dermatitis, xerosis, xerostomia, cheilitis and ulcers over the vulva, pubis, perianal area and lower abdomen [Table 1].9-18 Riganti et al.9 reported a painful lingual ulcer as part of differentiation syndrome and there was complete resolution after three days of starting dexamethasone (8 mg/day). In contrast, our patient had multiple smaller ulcers.

Table 1::
Summary of ATRA-induced cutaneous manifestations
Year Disease Treatment received for primary disease Clinical presentation Cutaneous manifestation Number of features fulfilling diagnostic criteria of DS Treatment of cutaneous manifestations Treatment response
1994 APL ATRA, 80 mg per day Fever and leucocytosis Skin nodules over arms (Sweet’s syndrome) 1 Intravenous methylprednisolone 1 gram for three days Improvement of skin lesions
2000 APL ATRA, 45 mg/m2 and ADE regimen Fever, fluid overload Multiple scrotal ulcers 2 Prednisolone 40 mg Healed after three weeks
2000 APL ATRA 40 mg BD Fever Multiple scrotal ulcer 1 ATRA continued No mention of steroids Ulcer healed after completion of treatment
2002 APL ATRA, 45 mg/m2, daunorubicin 60 mg/m2/day and cytarabine 200 mg/m2/day Fever and weight gain Violaceous and erythematous papulo-vesicles on the limbs and upper trunk (Sweet’s syndrome) 2 ATRA was stopped Dexamethasone 20 mg per day Improvement after two weeks
2005 APL ATRA, 40 mg BD and chemotherapy Fever, lower extremity oedema, and mild pulmonary infiltrates Solitary scrotal ulcer 3 ATRA was stopped No mention of steroids Ulcer healed shortly after stopping ATRA
2011 APL ATRA, 45 mg/m2, daunorubicin and cytarabine Fever, breathlessness, fatigue, pallor, tachypnoea and pancytopenia Solitary superficial scrotal ulcer 2 ATRA was stopped No mention of steroids Ulcer healed in three weeks
2012 APL ATRA, 40 mg BD and idarubicin Fever, weight gain, mild pleural, pericardial, and peritoneal effusion Solitary lingual ulcer 3 ATRA was stopped Dexamethasone 8 mg per day Ulcer healed after seven days
2018 APL ATRA, 40 mg BD, cytarabine and daunorubicin Fever and breathlessness Painful labial ulcer with scrotal ulcer 2 ATRA was stopped Started on Dexamethasone (dose not mentioned) Ulcers healed after 20 days
2020 GPP Acitretin, 25 mg per day Fever, facial puffiness, breathlessness and dry cough, tachycardia, dyspnoea, hypotension, oedema, bilateral basal crepitations Generalised erythema and scaling with relative sparing of the palms and soles and periorbital oedema 3 ATRA was stopped Intravenous betamethasone Improvement after 2 days
2020 APL ATRA, 45 mg/m2 and Daunorubicin 60 mg/m2/day Fever, breathlessness, pulmonary infiltrates and pancytopenia Multiple coalescing scrotal ulcers 3 ATRA was stopped Dexamethasone 10 mg BD Healed in four weeks
APL ATRA, 40 mg BD Fever, breathlessness, leucocytosis, pulmonary infiltrates, pleuro-pericardial effusion and elevated creatinine Oral ulcers, pedal oedema with diffuse erythema and scaling including soles 4 ATRA was stopped Prednisolone 40 mg per day Improvement after three days

BD: twice a day, ATRA: All-trans retinoic acid, APL: acute promyelocytic leukaemia, GPP: generalised pustular psoriasis, ADE: daunorubicin, etoposide and cytarabine, DS: differentiation syndrome

Even though all-trans retinoic acid or arsenic trioxide can induce differentiation syndrome, cutaneous manifestations are exclusively reported with all-trans retinoic acid-induced differentiation syndrome. These manifestations respond well after stopping all-trans retinoic acid and starting systemic steroids. The decision to stop drugs should be tailored to individual patients and depends on the severity of differentiation syndrome. The treatment of differentiation syndrome includes dexamethasone 10 mg twice a day till resolution or for a minimum of three days.19 Prednisolone 40 mg per day has also been used to treat differentiation syndrome and same was used in index because of the lack of severe systemic symptoms.10

In our patient, the oral ulcers, pedal oedema, erythema and scaling were attributed to differentiation syndrome as these started after two weeks of starting all-trans retinoic acid and arsenic trioxide and responded dramatically to systemic steroids. Dermatologists should be aware of these cutaneous manifestations that help in the early diagnosis and better management of the patient.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflict of interest

There are no conflicts of interest.

References

  1. , . Retinoic acid syndrome: A review. J Clin Pharm Therapeut. 2008;33:331-8.
    [CrossRef] [PubMed] [Google Scholar]
  2. , . Differentiation syndrome in promyelocytic leukemia: Clinical presentation, pathogenesis and treatment. Mediterr J Hematol Infect Dis. 2011;3:e2011048.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630-43.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol. 1993;11:1489-95.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , . Acitretin-induced retinoic acid syndrome. J Am Acad Dermatol. 2011;65:e148-9.
    [CrossRef] [PubMed] [Google Scholar]
  6. , . Retinoic acid syndrome: Manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16:453-61.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , , . Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. Biol Pharm Bull. 2006;29:234-9.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , , , , et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia–the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 1999;13:1406-8.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Lingual ulceration associated with retinoic acid syndrome during treatment of acute promyelocytic leukemia. Int J Dermatol. 2014;53:912-6.
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , . Scrotal ulceration during all-trans retinoic (ATRA) therapy for acute promyelocytic leukaemia. Clin Lab Haematol. 2000;22:171-4.
    [CrossRef] [PubMed] [Google Scholar]
  11. , . Sweet’s syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukaemia. Clin Exp Dermatol. 1994;19:51-2.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , . All-trans-retinoic acid-induced scrotal ulcerations in a patient with acute promyelocytic leukemia. J Am Acad Dermatol. 2000;43:316-7.
    [CrossRef] [PubMed] [Google Scholar]
  13. , , , , , . Sweet’s syndrome associated with retinoic acid syndrome in a patient with promyelocytic leukemia. Ann Hematol. 2002;81:111-4.
    [CrossRef] [PubMed] [Google Scholar]
  14. , , . Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia. Int J Dermatol. 2005;44:68-9.
    [CrossRef] [PubMed] [Google Scholar]
  15. , , , . Scrotal ulceration following all-trans retinoic Acid therapy for acute promyelocytic leukemia. Indian J Dermatol. 2011;56:561-3.
    [CrossRef] [PubMed] [Google Scholar]
  16. , , , . Rare labial ulcer related to the use of all-trans retinoic acid in a patient with acute promyelocytic leukemia. Spec Care Dentist. 2018;38:234-238.
    [CrossRef] [PubMed] [Google Scholar]
  17. , , , . Acitretin-induced differentiation syndrome in a case of generalized pustular psoriasis. Indian J Dermatol Venereol Leprol. 2020;86:231.
    [CrossRef] [Google Scholar]
  18. , , , . Retinoic acid syndrome followed by scrotal ulcer during treatment of acute promyelocytic leukemia with all-trans retinoic acid. J Curr Oncol. 2020;3:97-9.
    [CrossRef] [Google Scholar]
  19. , , . Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11:123.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
169

PDF downloads
53
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections